Search Results | Blood | American Society of Hematology

1-20 of 126

Sort by

Sort Order Select

Journal Articles

Daratumumab in AL amyloidosis

Ashutosh D. Wechalekar, Vaishali Sanchorawala

Blood (2022) 140 (22): 2317–2322.

DOI: https://doi.org/10.1182/blood.2021014613

Published: 2022

Journal Articles

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Hans C. Lee, Vaishali Sanchorawala, Shirley D'Sa, Satheesh Chonat, Carlos M. de Castro

Blood (2022) 140 (Supplement 1): 13057–13058.

DOI: https://doi.org/10.1182/blood-2022-157219

Published: 2022

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10180–10181.

DOI: https://doi.org/10.1182/blood-2022-165512

Published: 2022

Journal Articles

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Vaishali Sanchorawala, Michael Rosenzweig, Christopher Pericone, Sandra Y. Vasey, Xiang Qin, Sonja Marie Kotoulek, Bart Vandael, Joana Duran, Samer Khaled, NamPhuong Tran, Efstathios Kastritis

Blood (2022) 140 (Supplement 1): 10163–10164.

DOI: https://doi.org/10.1182/blood-2022-163615

Published: 2022

Journal Articles

Mapping and Modelling the Molecular Mechanisms That Drive Clonal Plasma Cell-Derived Amyloidogenic Light Chain Induced Cardiotoxicity

Camille V Edwards, Richard Giadone, Sabrina Ghosh, Gareth Morgan, Vaishali Sanchorawala, George J Murphy

Blood (2022) 140 (Supplement 1): 7127–7128.

DOI: https://doi.org/10.1182/blood-2022-167127

Published: 2022

Journal Articles

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Luke Zheng, Gheorghe Doros, Lawreen H Connors, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 155.

DOI: https://doi.org/10.1182/blood-2021-151804

Published: 2021

Journal Articles

Longitudinal Assessment and Prognostic Importance of Minimal Residual Disease (MRD) By Multiparametric Flow Cytometry in Patients with Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Eric Burks, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 3767.

DOI: https://doi.org/10.1182/blood-2021-149615

Published: 2021

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1650.

DOI: https://doi.org/10.1182/blood-2021-146866

Published: 2021

Journal Articles

Droxidopa for Treatment of Refractory Orthostatic Hypotension in Patients with AL Amyloidosis: A Case Series

Jorge Nicolas Ruiz Lopez, Lisa M Mendelson, Tracy Joshi, David Hughes, Michelle C Kaku, Vaishali Sanchorawala, John Mark Mark Sloan

Blood (2021) 138 (Supplement 1): 4737.

DOI: https://doi.org/10.1182/blood-2021-151573

Published: 2021

Journal Articles

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan Schönland, Heather J Landau, Kwok Fiona, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond Comenzo, Dasha Cherepanov, Vanessa C Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller, Efstathios Kastritis

Blood (2021) 138 (Supplement 1): 4771.

DOI: https://doi.org/10.1182/blood-2021-148689

Published: 2021

Journal Articles

Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Raphael Szalat, Joshua Gustine, John Mark Sloan, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 2734.

DOI: https://doi.org/10.1182/blood-2021-144980

Published: 2021

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

DOI: https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

DOI: https://doi.org/10.1182/blood-2021-149222

Published: 2021

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

DOI: https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Successful Conversion and Implementation to Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

David Hughes, Lynnette Henshaw, Frances Blevins, Camille V Edwards, Adam Lerner, John Mark Sloan, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 1975.

DOI: https://doi.org/10.1182/blood-2021-147518

Published: 2021

Journal Articles

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Charles J. Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood (2021) 137 (21): 2987–2989.

DOI: https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

DOI: https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-141549

Published: 2020

Journal Articles

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Terri L. Parker, MD, Adam Rosenthal, MS, Vaishali Sanchorawala, MD, Heather J Landau, MD, Erica Campagnaro, MD, Prashant Kapoor, MD, Natalia Neparidze, MD, Patrick Hagen, MD, Shayna Sarosiek, MD, Emma C. Scott, MD, Antje Hoering, PhD, Brian G.M. Durie, MD, Saad Z. Usmani, MDMBBS,MBA, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

DOI: https://doi.org/10.1182/blood-2020-143180

Published: 2020

Journal Articles

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Frances Blevins, PA-C, David Hughes, PharmD, Charles Milrod, MD, Preya Patel, MD, Shayna DeMari, BA, Adam Lerner, MD, Shayna Sarosiek, MD, Vaishali Sanchorawala, MD, John Mark Sloan, MD

Blood (2020) 136 (Supplement 1): 23–24.

DOI: https://doi.org/10.1182/blood-2020-136775

Published: 2020

NARROW

Daratumumab in AL amyloidosis

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Mapping and Modelling the Molecular Mechanisms That Drive Clonal Plasma Cell-Derived Amyloidogenic Light Chain Induced Cardiotoxicity

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Longitudinal Assessment and Prognostic Importance of Minimal Residual Disease (MRD) By Multiparametric Flow Cytometry in Patients with Systemic Light Chain (AL) Amyloidosis

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Droxidopa for Treatment of Refractory Orthostatic Hypotension in Patients with AL Amyloidosis: A Case Series

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Successful Conversion and Implementation to Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only